Skip to main content
Erschienen in: Breast Cancer Research 2/2011

01.12.2011 | Oral presentation

Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer

verfasst von: J Baselga, F Costa, H Gomez, C Hudis, B Rapoport, H Roche, LS Schwartzberg, O Petrenciuc, M Shan, WJ Gradishar

Erschienen in: Breast Cancer Research | Sonderheft 2/2011

Einloggen, um Zugang zu erhalten

Excerpt

A double-blind, randomized, phase 2b screening trial (SOLTI-0701) of sorafenib, an oral multikinase inhibitor, in patients with HER2-negative advanced breast cancer (BC), showed a statistically significant improvement in progression-free survival (PFS) in the sorafenib + capecitabine arm versus the placebo + capecitabine arm: 6.4 versus 4.1 months (hazard ratio = 0.58; one-sided P = 0.0006). Grade 3/4 toxicities were comparable except G3 hand-foot skin reaction/syndrome (HFSR/HFS) (44% vs. 14%). These results support a phase 3 trial of sorafenib + capecitabine in advanced BC. …
Metadaten
Titel
Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer
verfasst von
J Baselga
F Costa
H Gomez
C Hudis
B Rapoport
H Roche
LS Schwartzberg
O Petrenciuc
M Shan
WJ Gradishar
Publikationsdatum
01.12.2011
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe Sonderheft 2/2011
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3011

Weitere Artikel der Sonderheft 2/2011

Breast Cancer Research 2/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.